- Astellas Pharma‘s projected annual net income is 130.00 billion yen, falling short of the estimated 170.19 billion yen.
- The company anticipates an operating income of 160.00 billion yen for the fiscal year.
- Net sales for the year are estimated to be 1.93 trillion yen, aligning with market forecasts.
- The forecasted dividend per share is 78.00 yen, slightly below the expected 78.94 yen.
- Fourth Quarter Highlights:
- Astellas reported an operating income of 63.52 billion yen, a significant turnaround from a loss of 48.60 billion yen the previous year, and surpassing the estimate of 56.97 billion yen.
- Net income for the quarter was 74.90 billion yen, well above the 44.08 billion yen estimate.
- Quarterly net sales reached 459.29 billion yen, exceeding the estimate of 443.75 billion yen.
- Sales for Betanis/Myrabetriq/Betmiga totaled 45.5 billion yen, despite an 18% year-over-year decline, beating the estimate of 32.79 billion yen.
- Prograf sales were 45.4 billion yen, down 4.8% from last year, slightly above the estimated 45.06 billion yen.
- Xtandi reported strong sales growth of 9.8% year-over-year, with sales reaching 209.2 billion yen, surpassing the 200.56 billion yen estimate.
- Research and development expenses decreased by 2.2% to 76.2 billion yen, under the expected 87.11 billion yen.
- Annual Sales:
- Prograf’s annual sales fell 1% to 201.00 billion yen, slightly underperforming against the estimate of 202.75 billion yen.
- Betanis/Myrabetriq/Betmiga recorded annual sales of 170.04 billion yen, a 14% decrease year-over-year, but above the forecasted 157.23 billion yen.
- Analyst ratings include 9 buys, 7 holds, and 1 sell for Astellas Pharma.
“`
Astellas Pharma on Smartkarma
Analyst Coverage of Astellas Pharma on Smartkarma
On Smartkarma, the independent investment research network, analyst Tina Banerjee recently published insights on Astellas Pharma (4503 JP). In one report titled “Astellas Pharma (4503 JP): 9MFY25 Result- Strategic Brands Strong; Margins Expand; Guidance Raised,” it is noted that Astellas Pharma reported strong revenue growth and profit increase in the third quarter of fiscal year 2025. The company’s performance was bolstered by robust results in the U.S. market, leading to an upward revision in guidance due to favorable forex movements.
In another report by Tina Banerjee, titled “Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt,” Astellas Pharma revised its full-year revenue guidance upwards, citing strong Xtandi performance and positive forex movement. Despite recording impairment losses for intangible assets, the company is expected to see core profits and margins improve. Additionally, recent approvals for key products in various regions signal further growth potential for Astellas Pharma moving forward.
A look at Astellas Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Astellas Pharma has a mixed long-term outlook. The company excels in providing dividends, receiving a high score of 5, indicating it is strong in this aspect. However, it lags in growth potential, resilience, and momentum, with scores of 2 across the board. This suggests that while investors can expect consistent dividends from Astellas Pharma, they may not see significant growth or resilience to market fluctuations in the foreseeable future.
Astellas Pharma Inc. is a pharmaceutical company focusing on various therapeutic fields such as Urology, Immunology, including Transplantation and Infectious Diseases, Oncology, Neuroscience, and DM Complications and Metabolic Diseases. With a global workforce of over 17,000 employees, Astellas engages in research, development, manufacturing, and promotion of its prescription drugs through subsidiaries located in the US, Europe, and Asia.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
